YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Major earnings expected before the bell on Monday include: * BioLineRx Ltd. (BLRX [https://seekingalpha.com/symbol/BLRX]) * NexTech3D.AI Corp. (NEXCF [https://seekingalpha.com/symbol/NEXCF]) * LexinFintech Holdings Ltd. (LX [https://seekin…
[Young blond female manager explaining quarterly results on large led screen] NicolasMcComber As August gives way to September, next week brings a tech-heavy earnings slate, with investors focused on AI infrastructure, cybersecurity, enter…
* BioLineRx (BLRX [https://seekingalpha.com/symbol/BLRX]) is scheduled to announce Q2 earnings results on Monday, August 31th, before market open. * Over the last 1 year, BLRX has beaten EPS estimates [https://seekingalpha.com/symbol/BLRX/…
* BioLineRx (BLRX [https://seekingalpha.com/symbol/BLRX]) announced on Friday a registered direct offering [https://seekingalpha.com/pr/20633377-biolinerx-announces-3_75-million-registered-direct-offering-and-concurrent-private-placement]…
Major earnings expected before the bell on Wednesday include: * PDD Holdings (PDD [https://seekingalpha.com/symbol/PDD]) * The Bank of Nova Scotia (BNS [https://seekingalpha.com/symbol/BNS]) * Bank of Montreal (BMO [https://seekingalpha.co…
Major earnings expected before the bell on Monday include: * BioLineRx Ltd. (BLRX [https://seekingalpha.com/symbol/BLRX]) * Caledonia Mining Corporation Plc (CMCL [https://seekingalpha.com/symbol/CMCL]) * Lithium Argentina AG (LAR [https:/…
The following companies are expected to report earnings prior to market open on 11/24/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Corporacion America Airports SA (CAAP)is reporting for the quarter endin…
Major earnings expected before the bell on Thursday include: * JD.com (JD [https://seekingalpha.com/symbol/JD]) * Deere & Company (DE [https://seekingalpha.com/symbol/DE]) * First Majestic Silver Corp. (AG [https://seekingalpha.com/symbol/…
* BioLineRx (NASDAQ:BLRX [https://seekingalpha.com/symbol/BLRX]) is scheduled to announce Q2 earnings results on Thursday, August 14th, before market open. * The consensus EPS Estimate is -$0.53 [https://seekingalpha.com/symbol/BLRX/earnin…
Company Logo Multiple Myeloma is a cancer affecting plasma cells in bone marrow, often leading to weakened bones, anemia, and kidney damage. The production of abnormal M-proteins is a disease hallmark, detectable in blood or urine. While i…
BioLineRx Ltd. (NASDAQ:BLRX) is among the best growth stocks to invest in for the next 5 years. H.C. Wainwright reaffirmed its Buy rating on BioLineRx Ltd. (NASDAQ:BLRX) while maintaining a price target of $26.00. This confidence follows t…
H.C. Wainwright reiterated its buy rating and $26.00 price target on BioLineRx (NASDAQ:BLRX), a biotech company currently trading at $4.67, following the company’s presentation of full data from the pilot phase of its CheMo4METPANC Phase 2…
JonesResearch upgraded BioLineRx (BLRX) to Buy from Hold with a $12 price target The company announced new pilot phase data from the investigator-initiated Phase II combination trial of motixafortide plus PD-1 inhibitor cemiplimab plus che…
(RTTNews) - BioLineRx Ltd. (BLRX), a clinical-stage biopharmaceutical company, announced on Friday that updated results from the pilot phase of its Phase 2 CheMo4METPANC trial demonstrated promising clinical activity for its lead candidate…
The future of the U.S. economy appears to be at a pivotal juncture as the Federal Reserve maintains interest rates at a 22-year high, with the possibility of further tightening on the horizon. Despite strong economic indicators, including…
One of the safest sectors on the market is biotech. After all, we can’t stop people from aging — at least not yet. We have millions of people retiring and demanding better care. There’s a good deal of innovation, especially with gene editi…
When it comes to investing in top penny stocks, a word of caution. Do your due diligence before buying. Make sure it has volume. And know upfront that you can lose a lot of money. Sure, some penny stocks turned out to be massive success st…
TEL AVIV, Israel, July 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial stage biopharmaceutical company pursuing life-changing therapies for certain cancers and rare diseases, today announced the initia…
Now is a great time to accumulate top undervalued biotech stocks. For one, the sector is recession-proof. That’s because we can’t stop people from aging, or from seeking healthcare needs. Two, we have an aging population demanding better t…
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 1Q:23 Operational and Financial Results On May 24, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 1Q:23 operational and financial results in a press release concurrent w…
On Track for September PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) Rapidly Advancing U.S. Commercial Activities in Support of Potential September…
Management to Hold Conference Call at 10:00 a.m. EDT TEL AVIV, Israel, May 17, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it w…
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ:AXSM), for example. At one time, it was a $2.50 stock. Now it’s up to $71 with a treatment for major depressive disor…
TEL AVIV, Israel, April 25, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has received formal notice from The Nasdaq Stock Market, LLC…
- GENESIS trial achieved statistical significance (p<0.0001) across all primary and secondary endpoints - - Nature Medicine publication describes how GENESIS trial included patients representative of current multiple myeloma population und…
Typically, penny stocks are pure market wages for hardened gamblers. In fact, penny stocks are always risky — especially some of the best biotech stocks under $1 – and should oftentimes be avoided. And, as pointed out by the U.S. Securitie…
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2022 Earnings Call Transcript March 22, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx 2022 Financial Results Conference Call. I would now like to turn over the call…
By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT 2022 Operational and Financial Results On March 22, 2023, BioLineRx Ltd. (NASDAQ:BLRX) reported 2022 operational and financial results in a press release concurrent w…
- Announced FDA Acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in Stem Cell Mobilization with Prescription Drug User Fee Act (PDUFA) Target Action Date of September 9, 2023 - - Named Tami Rachmilewitz, M.D., as new Chief…
Management to Hold Conference Call at 10:00 am EDT TEL AVIV, Israel, March 15, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it w…
LOS ANGELES, March 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the de…
- Clinical trial part of long-term growth strategy for motixafortide across multiple potential therapeutic areas - TEL AVIV, Israel, March 6, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharma…
紐約, March 03, 2023 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 提醒：在 2021 年 2 月 23 日至 2022 年 9 月 19 日（含上述兩日期，簡稱「集體訴訟期」）期間購買了 BioLineRx Ltd. (NASDAQ: BLRX) 證券的人士注意，首席原告的重要截止日期為 2023 年 3 月 6 日。 影響：如果您購買了 BioLine 證券，您可能有權獲得賠償，並且根據後酬約定無需…
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Avaya Holdings Corp. (NYSE…
NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioLineRx Ltd. (NASDAQ: BLRX) between February 23, 2021 and September 19, 2022, both dates inclusi…
LOS ANGELES, March 01, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming March 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or…